{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:07Z","timestamp":1791979087396,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["114-SS0012"],"award-info":[{"award-number":["114-SS0012"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-002-126-MY3"],"award-info":[{"award-number":["113-2314-B-002-126-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW113-TDU-B-211-114006"],"award-info":[{"award-number":["MOHW113-TDU-B-211-114006"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jmii.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:35:09Z","timestamp":1754955309000},"page":"237-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["High-dose daptomycin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bloodstream infections: Role of pharmacodynamic target attainment"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4424-4718","authenticated-orcid":false,"given":"Liang-En","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-6367","authenticated-orcid":false,"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-3469","authenticated-orcid":false,"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-4139","authenticated-orcid":false,"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jmii.2025.08.005_bib1","first-page":"751","article-title":"Resistance in vancomycin-resistant enterococci","volume":"34","author":"Miller","year":"2020","journal-title":"Infect Dis Clin"},{"issue":"2","key":"10.1016\/j.jmii.2025.08.005_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00059-22","article-title":"Therapeutics for vancomycin-resistant enterococcal bloodstream infections","volume":"36","author":"Cairns","year":"2023","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"10.1016\/j.jmii.2025.08.005_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review","volume":"73","author":"Foolad","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"NA","key":"10.1016\/j.jmii.2025.08.005_bib4","first-page":"235","article-title":"Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: an updated systematic review and meta-analysis","volume":"21","author":"Shi","year":"2019","journal-title":"J Glob Antimicrobial Resistance"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.005_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2016.06.010","article-title":"Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.005_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2025.08.005_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jmii.2025.08.005_bib8","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.00714-13","article-title":"Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections","volume":"57","author":"Whang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jmii.2025.08.005_bib9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the clinical and laboratory standards institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.005_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jmii.2025.08.005_bib11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.08.005_bib12","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; M100. Wayne, PA","year":"2024"},{"key":"10.1016\/j.jmii.2025.08.005_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113710","article-title":"Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant enterococcus bloodstream infection","volume":"155","author":"Chuang","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.jmii.2025.08.005_bib14","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jmii.2025.08.005_bib15","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jmii.2025.08.005_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.005_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciq154","article-title":"Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia","volume":"52","author":"Chuang","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jmii.2025.08.005_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/cid\/ciz535","article-title":"Resilience of the pitt bacteremia score: 3 decades and counting","volume":"70","author":"Al-Hasan","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.005_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jmii.2025.08.005_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of Standard-, Medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jmii.2025.08.005_bib21","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkac164","article-title":"Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin","volume":"77","author":"Chuang","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jmii.2025.08.005_bib22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2025.08.005_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/CCM.0000000000003264","article-title":"Survival of patients with vancomycin-resistant Enterococcus faecium bacteremia treated with conventional or high doses of daptomycin or linezolid is associated with the rate of bacterial clearance","volume":"46","author":"Chuang","year":"2018","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.jmii.2025.08.005_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jmii.2025.08.005_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/civ449","article-title":"Editorial commentary: linezolid vs daptomycin for vancomycin-resistant enterococci: the evidence gap between trials and clinical experience","volume":"61","author":"McKinnell","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.005_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jmii.2011.11.005","article-title":"Emergence of vancomycin-resistant enterococcus bloodstream infections in southern Taiwan","volume":"45","author":"Chou","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"10.1016\/j.jmii.2025.08.005_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia","volume":"51","author":"Ye","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"10.1016\/j.jmii.2025.08.005_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.jmii.2025.08.005_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/phar.4602","article-title":"Fixed dose daptomycin: an opportunity for pharmacokinetic\/pharmacodynamic optimization in Staphylococcus aureus infections","volume":"44","author":"Olney","year":"2024","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.jmii.2025.08.005_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.diagmicrobio.2013.04.019","article-title":"Susceptibility of enterococci to daptomycin is dependent upon testing methodology","volume":"76","author":"Bryant","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.005_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0463.2009.02559.x","article-title":"Vancomycin-resistant enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin","volume":"118","author":"Rathe","year":"2010","journal-title":"Apmis"},{"issue":"9","key":"10.1016\/j.jmii.2025.08.005_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00745-18","article-title":"Variability of daptomycin MIC values for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests","volume":"62","author":"Campeau","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jmii.2025.08.005_bib33","first-page":"117","article-title":"Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment","volume":"74","author":"Gr\u00e9goire","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"2-4","key":"10.1016\/j.jmii.2025.08.005_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14787210.2024.2448727","article-title":"'Real-life' approach to applying PK\/PD principles in infectious diseases clinical practice without access to prompt TDM","volume":"23","author":"Geremia","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"10.1016\/j.jmii.2025.08.005_bib35","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2025.08.005_bib36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciae178","article-title":"Revolutionizing daptomycin dosing: a single 7-11-Hour sample for pragmatic application","volume":"79","author":"Angelini","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:31:09Z","timestamp":1772753469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1684118225001537"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.005","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose daptomycin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bloodstream infections: Role of pharmacodynamic target attainment","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}